Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 8, 2014, Pages 1271-1281

  Wang, Ya Wen ^a   Shi, Duan Bo ^a   Liu, Ya Min ^a,b   Sun, Yan Lin ^a   Chen, Xu ^a   Xiang, Shuai ^a   Fu, Qiang ^a   Wei, Jun Min ^a,c   Gao, Peng ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Antisense phosphorothioate oligodeoxynucleotides; Breast carcinoma; CD227; Invasiveness; Prognosis; Tumor characteristics

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CD227 ANTIGEN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ONCOPROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASIAN; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYTOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MCF-7 CELLS; MIDDLE AGED; MUCIN-1; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDES, ANTISENSE; PAPILLOMA, INTRADUCTAL;

EID: 84904360234     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1676-5     Document Type: Article

References (34)

1. Acs G, Esposito N, Rakosy Z, Laronga C, Zhang PJ (2010) Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 34(11):1637-1646. doi:10.1097/PAS.0b013e3181f5539c
2. Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58(18):4079-4081 (Pubitemid 28440559)
3. Angus B, Napier J, Purvis J, Ellis IO, Hawkins RA, Carpenter F, Horne CH (1986) Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. J Pathol 149(4):301-306. doi:10.1002/path.1711490406 (Pubitemid 16050289)
4. Arnerlov C, Ellis IO, Emdin SO (1988) Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value. Histopathology 13(6):695-697
5. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R, Austrian B, Colorectal Cancer Study G (2001) Evaluation of the United States Food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7(6):1669-1675 (Pubitemid 32708634)
6. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50(14):4332-4337 (Pubitemid 20225674)
7. Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R, Brummendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L (1999) Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 17(5):1535-1544 (Pubitemid 29220862)
8. Carraway KL 3rd, Funes M, Workman HC, Sweeney C (2007) Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Topics Develop Biol 78:1-22. doi:10.1016/S0070-2153(06) 78001-2
9. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1):156-159. doi:10.1006/abio.1987.9999 (Pubitemid 17064313)
10. Cooke T, Reeves J, Lanigan A, Stanton P (2001) HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12(Suppl 1):S23-S28 (Pubitemid 32750581)
11. de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast. Histopathology 51(2):227-238. doi:10.1111/j.1365-2559.2007.02754.x (Pubitemid 47083997)
12. Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J, Chaganti RS (2000) MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95(8):2666-2671 (Pubitemid 30210548)
13. Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076-1087
14. Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H, Shi DB (2013) The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 32(4):491-501. doi:10.1038/onc.2012.61
15. Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB et al (1991) Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 9(7):1113-1123
16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clinic 61(2):69-90. doi:10.3322/caac.20107
17. Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63(16):5011-5020 (Pubitemid 37022639)
18. Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K (2006) The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer 13(1):58-63
19. McGuckin MA (2001) CD227 (MUC1) - summary and workshop report. In: Mason D (ed) Leucocyte typing VII. Oxford University, Oxford, pp 54-56
20. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG (1995) Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 26(4):432-439
21. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T (1994) MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106(2):353-361 (Pubitemid 24041211)
22. Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V (2004) Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol 17(9):1045-1050. doi:10.1038/modpathol.3800166 (Pubitemid 39128230)
23. Parham DM, Slidders W, Robertson AJ (1988) Quantitation of human milk fat globule (HMFG1) expression in breast carcinoma and its association with survival. J Clin Pathol 41(8):875-879
24. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC (2001) The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91(11):1973-1982 (Pubitemid 32476360)
25. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18(10):1295-1304. doi:10.1038/modpathol.3800445 (Pubitemid 41348648)
26. Smith NL, Catrou PG, Payne G, Kellogg AE (2004) Patterns of expression of the DS6-glycoform of MUC1 correlates with known prognostic indicators in breast cancer. In: ACR Meeting Abstracts, 2004. p 239
27. Suwa T, Hinoda Y, Makiguchi Y, Takahashi T, Itoh F, Adachi M, Hareyama M, Imai K (1998) Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int J Cancer 76(3):377-382 (Pubitemid 28282937)
28. Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93(4):1287-1298 (Pubitemid 29076144)
29. van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 51(3):322-335. doi:10.1111/j.1365-2559.2007.02757.x (Pubitemid 47301607)
30. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64(11):3780-3789. doi:10.1158/0008-5472.CAN-03-1460 (Pubitemid 38697287)
31. Wykes M, MacDonald KP, Tran M, Quin RJ, Xing PX, Gendler SJ, Hart DN, McGuckin MA (2002) MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukocyte Biol 72(4):692-701 (Pubitemid 36277840)
32. Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8(5):629-642. doi:10.1158/1541-7786.MCR-10-0139
33. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8(16):3329-3341. doi:10.1002/pmic.200800040
34. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, Kitajima S, Goto M (2011) Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int 61(12):697-716. doi:10.1111/j.1440-1827.2011. 02734.x